Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Phase 2 Completed
102 enrolled 11 charts
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
Phase 2 Completed
29 enrolled 17 charts
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Phase 2 Completed
30 enrolled 11 charts
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Phase 2 Completed
22 enrolled 5 charts
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
6 enrolled 6 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Phase 2 Completed
33 enrolled 12 charts
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Phase 1/2 Completed
40 enrolled
ADVL
Phase 1 Completed
6 enrolled
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Withdrawn
ALBUM
Phase 2 Completed
16 enrolled 7 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Phase 1/2 Terminated
1 enrolled 8 charts
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Phase 1/2 Completed
92 enrolled 28 charts
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
Phase 1/2 Completed
50 enrolled 10 charts
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase 2 Completed
20 enrolled
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Phase 2 Completed
35 enrolled 11 charts
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
Phase 2 Terminated
1 enrolled 3 charts
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
Phase 2 Terminated
7 enrolled 6 charts
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 1 Completed
20 enrolled
REGALE
Phase NA Terminated
24 enrolled 7 charts
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors
Phase 2 Completed
2 enrolled
Campath Maintenance in Chronic Lymphocytic Leukemia
Phase NA Terminated
12 enrolled 5 charts
Alemtuzumab + Rituximab Consolidation in CLL
Phase 2 Terminated
1 enrolled 2 charts
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
25 enrolled 7 charts
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
41 enrolled 9 charts
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
86 enrolled 15 charts
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Phase 1/2 Completed
82 enrolled 12 charts
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia
Phase NA Completed
2 enrolled
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
Phase 2 Completed
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
Phase 2 Completed
54 enrolled
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
Phase 3 Completed
178 enrolled
CFAR Study in Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
60 enrolled 5 charts
MPDMDSBMT
Phase 2 Terminated
7 enrolled
Alemtuzumab and Pentostatin In T-cell Neoplasms
Phase 2 Terminated
26 enrolled 5 charts
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
Phase 2 Completed
30 enrolled 10 charts
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
Phase NA Completed
65 enrolled
Campath-1H + FK506 and Methylprednisolone for GVHD
Phase 2 Completed
34 enrolled
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Phase 2 Completed
53 enrolled
CRC005
Phase 2 Unknown
31 enrolled